Systemic chemotherapy is the standard of care for the treatment of unresectable metastatic colorectal cancer. However, new drug delivery platforms are needed to mitigate its associated toxicities. In this study, we develop and evaluate a liposome formulation that deliver oxaliplatin under magnetic field stimulus site selectively release in high concentration to alleviate the off-target effects in a rat model of colorectal liver metastases (CRLM). Quantitative MRI enabled assessment of changes in tumor characteristics over time for confirmation of procedural success and proper catheter-selective tumor targeting, which allows for high concentrations of oxaliplatin and improves survival outcomes in CRLM tumor-bearing rats.
This abstract and the presentation materials are available to members only; a login is required.